Hyperhidrosis Clinic, A Sygros Hospital, Athens, Greece.
Dermatol Surg. 2010 Apr;36(4):496-8. doi: 10.1111/j.1524-4725.2010.01473.x. Epub 2010 Feb 17.
Patients with focal hyperhidrosis in multiple areas often report improvement of plantar hyperhidrosis after botulinum toxin A (BTX-A) therapy for palmar hyperhidrosis.
To assess sweat production from the soles in patients receiving BTX-A treatment for their palmar hyperhidrosis.
Thirty-six patients with both palmar and plantar hyperhidrosis received 100 U of BTX-A per palm. Sweat production of palms and soles was assessed using a starch iodine test and gravimetry at baseline and 1, 3, and 8 months after treatment. Patients were subjectively assessed using a percentile scale.
All patients had significant improvement in their palmar hyperhidrosis that lasted for 6.2 +/- 1.8 months. Gravimetry revealed marginal improvement of plantar hyperhidrosis in 12 patients (from 39.7 +/- 21.3 to 31.5 +/- 18.0 mg/min; p=.01) and statistically significant worsening in 24 patients (from 71.6 +/- 70.60 to 109.94 +/- 82.93 mg/min, p<.001).
Treatment of palmar hyperhidrosis with BTX-A increased plantar sweating in many patients affected by both palmar and plantar hyperhidrosis in the population under study. Regardless, patients reported satisfaction with the results and were willing to repeat treatment.
患有多处局限性多汗症的患者在接受 A 型肉毒毒素（BTX-A）治疗手掌多汗症后，常报告足底多汗症得到改善。
评估接受 BTX-A 治疗手掌多汗症的患者足底的出汗量。
36 例手掌和足底均有多汗症的患者，每只手掌接受 100U 的 BTX-A。在基线时以及治疗后 1、3 和 8 个月，使用淀粉碘试验和称重法评估手掌和足底的出汗量。患者通过百分位量表进行主观评估。
所有患者手掌多汗症均显著改善，持续时间为 6.2+/-1.8 个月。称重法显示 12 例患者（从 39.7+/-21.3 至 31.5+/-18.0mg/min）足底多汗症有轻微改善（p=.01），24 例患者（从 71.6+/-70.60 至 109.94+/-82.93mg/min，p<.001）则明显恶化。
BTX-A 治疗手掌多汗症会增加许多同时患有手掌和足底多汗症患者的足底出汗量。尽管如此，患者对治疗结果表示满意并愿意重复治疗。
